The Precision GI™ Endoscopic Ultrasound Biopsy Device reportedly provides a more efficient and less traumatic method of obtaining biopsy tissue for suspected gastrointestinal cancers.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Precision GITM Endoscopic Ultrasound (EUS) Biopsy Device, which may facilitate improved quality and quantity of biopsy tissue.
For pancreatic cancer and other gastrointestinal (GI) cancers, the Precision GI ultrasound device enables clinicians to obtain “significantly superior quality and quantity of diagnostically relevant biopsy tissue,” according to Limaca Medical, the manufacturer of the Precision GI Endoscopic Ultrasound Biopsy Device.
Iyad Khamaysi, M.D., said the automation with the Precision GI ultrasound tool provides a notable contrast to other endoscopic biopsy modalities.
“While all existing endoscopic ultrasound fine needle biopsy (EUS-FNB) devices require manual hand operation, Precision GI features a unique motorized, automated rotational cutting needle for successful, safe, and high-quality tissue acquisition,” noted Iyad Khamaysi, M.D., the director of the Invasive Endoscopy Unit at the Rambam Health Care Campus in Haifa, Israel.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.